AGIO$27.8
$28.15
Chart
Performance
Key Stats
AI AGIO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAgios Pharmaceuticals presents a mixed but generally positive investment profile. Strong fundamentals, particularly in its balance sheet and potential drug pipeline, are counterbalanced by ongoing clinical and regulatory risks. Technical indicators show a bullish trend with some potential overbought signals. Thematic alignment with rare genetic diseases offers long-term growth prospects.
Thematic
Agios Pharmaceuticals is strategically positioned in the biopharmaceutical sector, focusing on rare genetic diseases and specific metabolic disorders. Its lead product, PYRUKYND, targets indications with significant unmet medical needs. The company's transition to a rare disease focus post-oncology divestiture aims to leverage niche market dynamics and potentially higher pricing power.
Fundamental
Agios Pharmaceuticals exhibits a strong balance sheet with substantial cash reserves and minimal debt, providing significant financial flexibility. While recent revenue growth is present, profitability remains a challenge due to high R&D expenses. Valuation metrics suggest the stock is attractively priced relative to its industry peers and its own historical averages, with potential upside if pipeline developments translate to commercial success.
Technical
Agios Pharmaceuticals is showing a generally bullish technical trend, with its stock price trading above key moving averages. However, some indicators suggest it may be approaching overbought levels, hinting at a potential for consolidation or a short-term pullback. The overall sentiment from technical indicators leans towards a positive outlook, but caution is advised for short-term trades.
| Factor | Score |
|---|---|
| Rare Genetic Diseases Focus | 90 |
| Biopharmaceutical Innovation | 80 |
| Market Potential (Thalassemia/SCD) | 85 |
| Regulatory Catalysts | 80 |
| Biotech Sector Trends | 75 |
| Factor | Score |
|---|---|
| Valuation | 90 |
| Profitability | 40 |
| Growth | 70 |
| Balance Sheet Health | 95 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| MACD | 75 |
| Support and Resistance | 50 |
| Volume Confirmation | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
Agios Pharmaceuticals (AGIO) has demonstrated a pattern of beating earnings per share (EPS) estimates in recent quarters. For example, in Q2 2025, the reported EPS of -1.55 beat the estimate of -1.78 by 13.1%. This consistent outperformance suggests operational efficiency and effective management.
Low Price-to-Earnings (P/E) Ratio
The trailing Price-to-Earnings (P/E) ratio of 3.4358754 is remarkably low, especially for a biopharmaceutical company. This indicates that the stock may be undervalued relative to its current earnings. For context, the company had a positive net income of $673,725,000 in 2024, and a P/E of 2.8 based on that year.
Bearish Points (7)
Inconsistent Profitability and Negative EPS Estimates
While AGIO has beaten EPS estimates recently, many of these beats were on negative EPS figures (e.g., Q2 2025 estimate -1.78, reported -1.55). Furthermore, the company has experienced significant net losses in some prior years (e.g., 2023, 2022), and future EPS estimates remain negative for some quarters (e.g., Q2 2025 estimate -1.78). The Q4 2024 earnings report showed a significant negative surprise (-318.44%) with EPS of -2.42 against an estimate of 1.11.
Negative Free Cash Flow
Agios Pharmaceuticals has consistently reported negative free cash flow (e.g., -$391,526,000 in Q4 2024, -$314,561,000 in Q4 2023). This indicates that the company is burning cash, which could require future financing or impact its ability to invest in growth if not managed effectively.
Calendar
July 2025
31
Next Earnings Date
H: $-1.67
A: $-1.78
L: $-1.92
H: 10.00M
A: 9.46M
L: 9.00M
Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
51.57 USD
The 39 analysts offering 1 year price forecasts for AGIO have a max estimate of 71.00 and a min estimate of 38.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
A spin-off from Agios Pharmaceuticals, sharing a common scientific lineage and continued focus on hematologic disorders, particularly those related to red blood cell biology.
Weight: 90
A leader in developing transformative medicines for genetically defined diseases (e.g., Cystic Fibrosis), aligning with Agios's core focus on genetic and rare diseases.
Weight: 88
Specializes in rare metabolic and genetic disorders, directly competing or complementing Agios's therapeutic areas with a focus on enzyme replacement therapies and precision medicines.
Weight: 85
Develops RNAi therapeutics for rare genetic diseases, targeting similar patient populations and disease mechanisms as Agios's focus on genetically defined conditions.